Literature DB >> 21800876

Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.

Arun K Ghosh1, Bruno D Chapsal, Garth L Parham, Melinda Steffey, Johnson Agniswamy, Yuan-Fang Wang, Masayuki Amano, Irene T Weber, Hiroaki Mitsuya.   

Abstract

We report the design, synthesis, biological evaluation, and the X-ray crystal structure of a novel inhibitor bound to the HIV-1 protease. Various C3-functionalized cyclopentanyltetrahydrofurans (Cp-THF) were designed to interact with the flap Gly48 carbonyl or amide NH in the S2-subsite of the HIV-1 protease. We investigated the potential of those functionalized ligands in combination with hydroxyethylsulfonamide isosteres. Inhibitor 26 containing a 3-(R)-hydroxyl group on the Cp-THF core displayed the most potent enzyme inhibitory and antiviral activity. Our studies revealed a preference for the 3-(R)-configuration over the corresponding 3-(S)-derivative. Inhibitor 26 exhibited potent activity against a panel of multidrug-resistant HIV-1 variants. A high resolution X-ray structure of 26-bound HIV-1 protease revealed important molecular insight into the ligand-binding site interactions.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21800876      PMCID: PMC3164320          DOI: 10.1021/jm200649p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

3.  Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.

Authors:  Yunfeng Tie; Peter I Boross; Yuan-Fang Wang; Laquasha Gaddis; Fengling Liu; Xianfeng Chen; Jozsef Tozser; Robert W Harrison; Irene T Weber
Journal:  FEBS J       Date:  2005-10       Impact factor: 5.542

4.  SHELXL: high-resolution refinement.

Authors:  G M Sheldrick; T R Schneider
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

5.  Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

Authors:  Arun K Ghosh; Perali Ramu Sridhar; Sofiya Leshchenko; Azhar K Hussain; Jianfeng Li; Andrey Yu Kovalevsky; D Eric Walters; Joseph E Wedekind; Valerie Grum-Tokars; Debananda Das; Yasuhiro Koh; Kenji Maeda; Hiroyuki Gatanaga; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

6.  A simple, continuous fluorometric assay for HIV protease.

Authors:  M V Toth; G R Marshall
Journal:  Int J Pept Protein Res       Date:  1990-12

7.  GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

Authors:  Yasuhiro Koh; Debananda Das; Sofiya Leschenko; Hirotomo Nakata; Hiromi Ogata-Aoki; Masayuki Amano; Maki Nakayama; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.

Authors:  Ravindra Gupta; Andrew Hill; Anthony W Sawyer; Deenan Pillay
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

9.  Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Authors:  Yasuhiro Koh; Hirotomo Nakata; Kenji Maeda; Hiromi Ogata; Geoffrey Bilcer; Thippeswamy Devasamudram; John F Kincaid; Peter Boross; Yuan-Fang Wang; Yunfeng Tie; Patra Volarath; Laquasha Gaddis; Robert W Harrison; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  12 in total

1.  Intramolecular regulation of the sequence-specific mRNA interferase activity of MazF fused to a MazE fragment with a linker cleavable by specific proteases.

Authors:  Jung-Ho Park; Yoshihiro Yamaguchi; Masayori Inouye
Journal:  Appl Environ Microbiol       Date:  2012-03-23       Impact factor: 4.792

Review 2.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

3.  Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.

Authors:  Arun K Ghosh; Bruno D Chapsal; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  Bioorg Med Chem Lett       Date:  2012-02-02       Impact factor: 2.823

4.  Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.

Authors:  Arun K Ghosh; Cuthbert D Martyr; Luke A Kassekert; Prasanth R Nyalapatla; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Masayuki Amano; Hiroaki Mitsuya
Journal:  Org Biomol Chem       Date:  2015-10-14       Impact factor: 3.876

5.  Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.

Authors:  Arun K Ghosh; Sofiya Yashchuk; Akira Mizuno; Nilanjana Chakraborty; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Pedro Miguel Salcedo Gomez; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2014-10-21       Impact factor: 3.466

6.  Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.

Authors:  Arun K Ghosh; Kalapala Venkateswara Rao; Prasanth R Nyalapatla; Heather L Osswald; Cuthbert D Martyr; Manabu Aoki; Hironori Hayashi; Johnson Agniswamy; Yuan-Fang Wang; Haydar Bulut; Debananda Das; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2017-04-18       Impact factor: 7.446

7.  Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.

Authors:  Arun K Ghosh; Zilei Xia; Satish Kovela; William L Robinson; Megan E Johnson; Daniel W Kneller; Yuan-Fang Wang; Manabu Aoki; Yuki Takamatsu; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2019-10-04       Impact factor: 3.466

8.  Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy.

Authors:  Hailiu Yang; Joseph Nkeze; Richard Y Zhao
Journal:  Cell Biosci       Date:  2012-09-12       Impact factor: 7.133

9.  tert-Butyl N-[2-(N-isobutyl-4-meth-oxy-benzene-sulfonamido)-eth-yl]carbamate.

Authors:  Xiao-Guang Bai; Ju-Xian Wang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-05-17

Review 10.  Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.

Authors:  Lucianna Helene Santos; Rafaela Salgado Ferreira; Ernesto Raúl Caffarena
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.